Systemic treatment of small cell lung cancer

Tien Hoang, Joan H. Schiller

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Small cell lung cancer (SCLC) accounts for 20-25% of all lung cancer and is characterized by an aggressive clinical course with early dissemination and extremely high risk of recurrence. Chemotherapy has been the cornerstone of treatment, with high response rates including complete responses. Despite the sensitivity of this disease to cytotoxic drugs, the majority of patients will face recurrence and die of the disease within two years. For more than thirty years, investigators have conducted numerous trials using different drug regimens and schedules, as well as different therapeutic modalities. The combination of cyclophosphamide, doxorubicin (adriamycin) and vincristine (CAV) was one of the first widely accepted regimens for the treatment of SCLC. Later, CAV and its hybrids were replaced by the similarly effective but less toxic regimen of cisplatin and etoposide (PE). Clinical investigators have tried different approaches to improve the efficacy of these regimens, such as alternating CAV/PE; consolidation and maintenance therapy; intensive treatment with high-dose chemotherapy; increased frequency of drug administration; or high dose therapy with stem cell support - all with no definitive successes, leaving PE as the standard treatment for patients with SCLC. The recent arrival of new chemotherapy agents such as topotecan, irinotecan, and taxanes may represent a step forward in the treatment of this disease. The most promising regimen is the combination of irinotecan and cisplatin which, according to Japanese investigators, achieves a significantly better survival than standard PE. If validated by confirmatory trials, this combination could well become the new standard treatment for extensive chemotherapy-naïve SCLC. Biological agents are also being widely investigated, including vaccines, matrix metalloproteinase inhibitors, anti-sense therapy, and monoclonal antibodies. Advances in molecular biology will hopefully contribute to progress in the treatment of this lethal disease.

Original languageEnglish (US)
Pages (from-to)397-408
Number of pages12
JournalAmerican Journal of Cancer
Volume1
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Small Cell Lung Carcinoma
irinotecan
Doxorubicin
Vincristine
Therapeutics
Drug Therapy
Research Personnel
Cisplatin
Pharmaceutical Preparations
Topotecan
Recurrence
Taxoids
Matrix Metalloproteinase Inhibitors
Poisons
Biological Factors
Etoposide
Cyclophosphamide
Molecular Biology
Lung Neoplasms
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology

Cite this

Systemic treatment of small cell lung cancer. / Hoang, Tien; Schiller, Joan H.

In: American Journal of Cancer, Vol. 1, No. 6, 2002, p. 397-408.

Research output: Contribution to journalArticle

Hoang, Tien ; Schiller, Joan H. / Systemic treatment of small cell lung cancer. In: American Journal of Cancer. 2002 ; Vol. 1, No. 6. pp. 397-408.
@article{d32d12ed2e584646b31c17404986573f,
title = "Systemic treatment of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) accounts for 20-25{\%} of all lung cancer and is characterized by an aggressive clinical course with early dissemination and extremely high risk of recurrence. Chemotherapy has been the cornerstone of treatment, with high response rates including complete responses. Despite the sensitivity of this disease to cytotoxic drugs, the majority of patients will face recurrence and die of the disease within two years. For more than thirty years, investigators have conducted numerous trials using different drug regimens and schedules, as well as different therapeutic modalities. The combination of cyclophosphamide, doxorubicin (adriamycin) and vincristine (CAV) was one of the first widely accepted regimens for the treatment of SCLC. Later, CAV and its hybrids were replaced by the similarly effective but less toxic regimen of cisplatin and etoposide (PE). Clinical investigators have tried different approaches to improve the efficacy of these regimens, such as alternating CAV/PE; consolidation and maintenance therapy; intensive treatment with high-dose chemotherapy; increased frequency of drug administration; or high dose therapy with stem cell support - all with no definitive successes, leaving PE as the standard treatment for patients with SCLC. The recent arrival of new chemotherapy agents such as topotecan, irinotecan, and taxanes may represent a step forward in the treatment of this disease. The most promising regimen is the combination of irinotecan and cisplatin which, according to Japanese investigators, achieves a significantly better survival than standard PE. If validated by confirmatory trials, this combination could well become the new standard treatment for extensive chemotherapy-na{\"i}ve SCLC. Biological agents are also being widely investigated, including vaccines, matrix metalloproteinase inhibitors, anti-sense therapy, and monoclonal antibodies. Advances in molecular biology will hopefully contribute to progress in the treatment of this lethal disease.",
author = "Tien Hoang and Schiller, {Joan H.}",
year = "2002",
doi = "10.2165/00024669-200201060-00003",
language = "English (US)",
volume = "1",
pages = "397--408",
journal = "American Journal of Cancer",
issn = "1175-6357",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Systemic treatment of small cell lung cancer

AU - Hoang, Tien

AU - Schiller, Joan H.

PY - 2002

Y1 - 2002

N2 - Small cell lung cancer (SCLC) accounts for 20-25% of all lung cancer and is characterized by an aggressive clinical course with early dissemination and extremely high risk of recurrence. Chemotherapy has been the cornerstone of treatment, with high response rates including complete responses. Despite the sensitivity of this disease to cytotoxic drugs, the majority of patients will face recurrence and die of the disease within two years. For more than thirty years, investigators have conducted numerous trials using different drug regimens and schedules, as well as different therapeutic modalities. The combination of cyclophosphamide, doxorubicin (adriamycin) and vincristine (CAV) was one of the first widely accepted regimens for the treatment of SCLC. Later, CAV and its hybrids were replaced by the similarly effective but less toxic regimen of cisplatin and etoposide (PE). Clinical investigators have tried different approaches to improve the efficacy of these regimens, such as alternating CAV/PE; consolidation and maintenance therapy; intensive treatment with high-dose chemotherapy; increased frequency of drug administration; or high dose therapy with stem cell support - all with no definitive successes, leaving PE as the standard treatment for patients with SCLC. The recent arrival of new chemotherapy agents such as topotecan, irinotecan, and taxanes may represent a step forward in the treatment of this disease. The most promising regimen is the combination of irinotecan and cisplatin which, according to Japanese investigators, achieves a significantly better survival than standard PE. If validated by confirmatory trials, this combination could well become the new standard treatment for extensive chemotherapy-naïve SCLC. Biological agents are also being widely investigated, including vaccines, matrix metalloproteinase inhibitors, anti-sense therapy, and monoclonal antibodies. Advances in molecular biology will hopefully contribute to progress in the treatment of this lethal disease.

AB - Small cell lung cancer (SCLC) accounts for 20-25% of all lung cancer and is characterized by an aggressive clinical course with early dissemination and extremely high risk of recurrence. Chemotherapy has been the cornerstone of treatment, with high response rates including complete responses. Despite the sensitivity of this disease to cytotoxic drugs, the majority of patients will face recurrence and die of the disease within two years. For more than thirty years, investigators have conducted numerous trials using different drug regimens and schedules, as well as different therapeutic modalities. The combination of cyclophosphamide, doxorubicin (adriamycin) and vincristine (CAV) was one of the first widely accepted regimens for the treatment of SCLC. Later, CAV and its hybrids were replaced by the similarly effective but less toxic regimen of cisplatin and etoposide (PE). Clinical investigators have tried different approaches to improve the efficacy of these regimens, such as alternating CAV/PE; consolidation and maintenance therapy; intensive treatment with high-dose chemotherapy; increased frequency of drug administration; or high dose therapy with stem cell support - all with no definitive successes, leaving PE as the standard treatment for patients with SCLC. The recent arrival of new chemotherapy agents such as topotecan, irinotecan, and taxanes may represent a step forward in the treatment of this disease. The most promising regimen is the combination of irinotecan and cisplatin which, according to Japanese investigators, achieves a significantly better survival than standard PE. If validated by confirmatory trials, this combination could well become the new standard treatment for extensive chemotherapy-naïve SCLC. Biological agents are also being widely investigated, including vaccines, matrix metalloproteinase inhibitors, anti-sense therapy, and monoclonal antibodies. Advances in molecular biology will hopefully contribute to progress in the treatment of this lethal disease.

UR - http://www.scopus.com/inward/record.url?scp=0041317598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041317598&partnerID=8YFLogxK

U2 - 10.2165/00024669-200201060-00003

DO - 10.2165/00024669-200201060-00003

M3 - Article

VL - 1

SP - 397

EP - 408

JO - American Journal of Cancer

JF - American Journal of Cancer

SN - 1175-6357

IS - 6

ER -